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TOPICAL SUPPRESSION OF ECCRINE SWEAT DELIVERY WITH A
NEW ANTICHOLINERGIC AGENT*
R. B. STOIJOHTON, Ml)., F. CHIU, M.D., W. FRITSCH, M.D. AND 1). NURSE, M.D.
An anticholinergic agent (AHR—483)1 has been
investigated for its property of suppressing or
totally inhibiting eeerine sweat gland function
when applied topically—over large areas of the
body—without inducing other significant local
or systemic side effects.
Studies of effectiveness and toxicity have been
carried out in human volunteers. In vitro penetra-
tion studies of C14 labelled material have also
been done.
This agent (AHR—483) (See Fig. 1) is closely
related to glycopyrrolate which has been used
extensively for control of peptic ulcer and has
been studied extensively in animals and man
(1—6).
METHOD5
A. AHR-483 was prepared for topical use by
dissolving in distilled water to make solutions
from 0.05 to 0.5%. Concentrations of 0.05, 0.1 and
0.5% were applied to the forearms of 30 young
adult volunteers. 0.1 cc of the solutions were
applied from a pipette and allowed to dry on the
forearm. After a period of 90—120 minutes the
subjects washed the area with tap water. The
starch-iodine method for detecting sweating was
used. The subjects were put into a thermal cham-
ber in which the temperature was kept at 88—94°
F and the humidity at 70—80%. The degree of
sweating was determined visually after 20—30
minutes in the thermal chamber.
B. Solutions for topical application to axillae
were prepared by dissolving 0.5% AHR-483 in
0.4% carboxymethylcellulose in distilled water.
This was dispensed in a commercial roll-on type
bottle. The subjects applied this material to the
right axillary vault b.i.d. The left axillary vault
had no medication of any kind applied during the
test period.
Delivery of fluid to the axillary vault was
measured by a gravimetric technic. This involved
the placement of absorbent cotton in both axil-
lary vaults and measuring the weight of the
cotton (in petri dishes) before and immediately
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after exposure of the subject for 30 minutes in the
thermal chamber. Gravimetric tests of both
axillae were done twice on most subjects before the
test material was applied. The subjects stopped
all axillary medication two weeks before entering
the study.
C. AHR-483 was prepared for intradermal
injection in the forearms of young adults by
dissolving AHR-483 in normal saline under sterile
conditions to make solutions varying in con-
centration from 10° to 10b0. These concentrations
were injected (0.1 cc) intradermally into the
forearms of 10 subjects. The areas were tested for
sweating responses by using the starch-iodine
visual method while the subjects were subjected
to the thermal chamber under the conditions
described above.
D. In vitro percutaneous absorption was
measured in human skin (leg or breast) removed
at surgery. The skin was placed in a modified
skin penetration chamber. C'4 labeled AHR-
483 was placed on the epidermal surface and the
fluid bathing the corium was sampled for radio-
activity at given intervals. This technic has been
used in our laboratory previously and is described
in detail elsewhere (7, 8).
E. Toxicity studies were carried out with
aqueous and alcoholic solutions of AHR-483.
Ten (10) cc of 0.5% aqueous solution were applied
with a pipette over the arms, trunk and legs of
20 normal adult subjects. The material was
spread over areas which covered the entire arms,
legs and trunk. The material was allowed to dry.
The subjects were watched closely for any local
or systemic signs of toxicity (cutaneous reactions,
pupillary changes, dry mouth, urinary difficulties,
gastro-intestinal reactions, dizziness, or any
subjective complaints) for 7—10 days.
Another 15 subjects were tested with 70%
alcoholic solutions (0.5% AHR-483) by topical
application in the same way as outlined above.
The subjects were observed in the same way.
Ten additional subjects were treated with 15
cc of 0.5% AHR-483 in aqueous solutions as
above.
Another group of 15 subjects was treated with
topical application of 8 cc of 0.5% AHR-483,
aqueous solution, to arms and legs. The arms and
legs were then encased in Saran Wrap for 14—16
hours. These subjects were watched closely for any
local or systemic reactions.
F. Fifty (50) subjects were used for repeat
insult patch tests. 0.1 cc of 0.5% aqueous solution
AHR-483 was applied to a piece of soft linen.
The linen patch was applied to the upper arm
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FIG. 1. AHR-483 (i-methyl-3-pyrrolidyl a-
phenyleyelohexaneglyeolate methobromide).
and covered with an elastoplast2 bandage for 48
hours. This test was repeated in 7 days and again
in 21 days. The areas were inspected at the time
of removal of the patch and at 48 and 96 hour
intervals following removal of the patch.
C. In 7 adult subjects with severe atopie
dermatitis (erythema, erosions, scaling, liehenifica-
tion and, in 2 subjects, oozing and crusting)
8 cc of aqueous solution of 0.5% AHR-483 was
applied to arms and legs and covered with Saran
Wrap for 14—16 hours. These subjects were watched
closely for any local or systemic signs of toxicity.
They were observed for 10-20 days following the
application.
RESULTS
with marked inhibition of sweating. The varia-
tion of effect among subjects remains unex-
plained. A few of these subjects have been tested
B after 3 months of continuous use and the inhibi-
tion remains to the same degree. The average
subject used 15 cc of 0.5% AHR—483 per week.
There was no evidence of local or systemic
reaction of any kind in any of these subjects.
In most subjects the right axilla delivered more
fluid than the left axilla in the base line measure-
ments. The AHR—483 was applied to the right
axilla in all of the eighteen subjects. All of the
subjects were young adults. Ten were males and
eight were females.
It is of interest to note that of the 43 observa-
tions only one (Subject No. 8; week 1; —3.3%)
indicates an increase in sweating in the right
axilla.
The average per cent inhibition of sweating in
the treated axilla for the weekly estimations
varies from 40.75% to 68.77%.
None of these subjects complained of any irrita-
tion or discomfort of any kind.
A. AHR—483 in 0.5% concentrations consist-
ently inhibited sweating of the forearm. The
inhibition was more marked after 3—4 daily
single applications than after one single applica-
tion. Figure 2 shows the inhibition of sweating of
the treated forearm after 3 days of daily, single
applications of 0.5% AHR—483 to the entire
forearm. The untreated forearm shows normal
sweating. Concentrations below 0.5% (0.1% and
0.05%) are capable of inhibiting sweating but
are not as consistently reliable as the 0.5% con-
centration. With 0.1 cc of 0.5% aqueous solution,
16 of 30 subjects showed inhibition after single
application. With 0.1 cc of 0.5% aqueous solu-
tion applied to the forearm (about 3 sq cm)
once daily for 3 days, 20 of 20 subjects showed
complete inhibition of sweating in the area of
application.
B. Inhibition of axillary sweating can be
accomplished by repeated daily applications of
0.5% AHR—483. The inhibition is consistent and
quite dramatic. Table I gives the quantitative
data in regard to base line measurements of
axillary delivery as well as measurements taken
after one to seven weeks of twice daily applica-
tions. It is evident that most subjects respond
I Duke Laboratories, Norwalk, Conn.
F'o. 2. Right forearm treated with AIIR-483(viewer's left) shows inhibition of sweating as
indicated by lack of black discoloration (starch-
iodine-castor oil technic) after exposure in thermal
chamber.
t:if
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TABLE I
Axillary sweat delivery and per cent inhibition*
Pre-Drug Base Weeks Post-Drug and Per Cent Inhibition
Subject
Number Arm
1st 2nd Mean 1 2 3 4 5 7
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Mgm
240
205
192
142
450
340
460
350
210
250
201
175
210
198
223
274
137
74
76
39
515
390
300
155
269
202
220
184
107
117
53
48
283
226
2864
2741
R
L
R
L
R
L
R
L
R
IL
R
L
R
IL
R
L
R
L
R
L
R
L
R
L
R
L
R
L
R
L
R
L
R
L
R
L
Mgm
108
639
90
154
315
635
%
79.8
60.0
66.5
Mgm
216
175
185
140
376
310
485
368
262
285
185
160
225
197
140
160
135
107
73
63
235
117
109
80
213
113
263
246
32
39
124
64
692
765
Mgnz
228.0
190.0
188.5
141.0
413.0
325.0
472.5
359.0
236.0
267.5
193.0
167.5
217.5
197.5
181.5
217.0
136.0
90.5
74.5
51.0
375.0
253.5
204.5
117.5
241.0
157.5
220.0
184.0
185.0
181.5
42.5
43.5
203.5
145.0
1778.0
1753.0
.hlgns
112
251
344
345
Mgm
202
536
612
422
92
78
149
670
51
259
112
334
92
155
52
116
492
485
Mgm
135
180
95
145
145
260
210
390
180
290
168
160
127
188
184
213
87
93
62
582
24
100
183
239
1335
1368
%
54.9
3.5
19.2
85.0
88.7
78.1
41.9
54.1
27.7
%
37.5
51.0
56.1
59.1
29.6
8.9
38.7
—3.3
36.0
92.8
86.3
36.0
3.7
31gm
62
185
70
56
420
84
375
85
240
152
168
42
220
140
462
99
140
1191
1194
% Mgm
72.1
67.3
89.5
83.0
59.9
21.4
82.7
133
197
180
237
796
1784
70.3 91
156
27.6
28.9 413
612
372
715
46.7
34.8
55.1
48.0
69.8
42.8
51.9
48.8
Number of subjects 13 9 10 6 2 3
Mean per cent inhibition 40.95 50.33 60.27 52.73 40.75 68.77
95% upper confidence limit 58.34 73.44 78.05 62.50 93.86
95% lower confidence limit 23.56 27.22 42.49 42.96 43.68
* Axillary sweat delivery in grams for right and left arms prior to therapy and at weekly intervals
following twice daily applications of 0.5% AHR-483 to the right arm only. The per cent axillary sweat
inhibition has been calculated as follows:
Per cent of base for IIPer cent inhibition = 100% = X 100Per cent of base for L
Mgm sweat after one week of therapyPer cent of base for R1 = . X 100 (e.g.)Mgm sweat during base
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Table I is a summary of all the data for 18
subjects in whom axillary sweating was measured
before and after application of AHR—483.
Ninety-five per cent (95%) upper and lower
confidence limits are expressed for each of the
time periods.
C. Table II shows the results of intradermal
injection of 0.1 cc of AHR—483 in different
concentrations. Most subjects show definite in-
hibition of sweat delivery in concentrations as
low as 10—8 although some variation is apparent
among the subjects tested.
D. The penetration of C'4 labelled AHR—483
was measured in vitro using excised human
breast skin. Seven determinations were made on
a single specimen. 025 ml of an ethanol solution
saturated at room temperature was applied to
3.14 cm' of the epidermis and the specimens were
incubated for 24 hours at 40° C with a relative
humidity of 88%. The average penetration in per
cent of applied counts penetrating in 24 hours was
0.02% with a range of 0.002 to 0.035 %.
E. We have not yet seen any local or systemic
signs of toxicity from 0.5% AHR—483 using the
the amounts and technics described. We have
used up to 75 mgm topically over large areas
without occlusive wrap, and up to 40 mgm over
arms and legs with occlusive wrap. No local or
systemic signs of toxicity have been observed.
F. Repeat insult patch tests have not revealed
any evidence of sensitization or irritation in 50
subjects.
TABLE II
AHR-483 injected intradermatly into forearm
(0.1 cc)
+ = Complete inhibition.
0 = No inhibition.
G. One of the 7 adult subjects with severe
atopic dermatitis developed a mild dryness of
the mouth with occlusive wrapping after topical
application of 8 cc of 0.5% AHR—483. This
subject had many areas of oozing and excoria-
tions under the occlusive wrap. The other 6
subjects did not develop any signs of systemic
effect of the drug.
One might expect such signs as pupillary
changes, dryness of mouth, difficulty of urination,
drowsiness, etc., due to the drug's anticholinergic
activity. However, the fact that only one subject
developed the mild symptom of dryness of mouth
with such exaggerated conditions of exposure is
encouraging in view of possible clinical use of
this agent.
niscussion
Shelley and Horvath demonstrated that oral
administration of anticholinergic agents is rel-
atively ineffective for control of sweating. They
state "anhidrosis is not a therapeutic result of
systemically administered aaticholincrgic drugs.
Rather, it is a sign of over-dosage." They also
demonstrated that scopolamine hydrobromide,
1% aqueous solution, will inhibit sweating when
applied topically. They expressed considerable
concern that scopolamine hydrobromide might
be hazardous if used over large areas or on skin
already involved in an inflammatory process
where penetration might be enhanced (9).
The features of AHR—483 which make it an
agent of potential use clinically are:
1. It is effective by topical application.
2. There is no evidence in our studies that it
induces local or systemic reaction even when
applied in amounts up to 75 mgm over large areas.
Also, the lack of any systemic effects after 40 mgm
were applied to the arms and legs under occlusive
wrap is impressive. Previous work has shown that
occlusive dressings are capable of enhancing
penetration by a factor of 100 fold (10).
3. The almost complete lack of signs of systemic
reactions after applications of 40 mgm under
occlusive wrap over large areas of skin severely
involved in atopic dermatitis.
4. Lack of irritation or sensitization in the
studies performed to date.
We were unable to show any inhibition of
sweating on the palms with topical application.
Shelley and Horvath were unable to show
inhibition of sweating of palms or soles with
scopolamine hydrobromide (3). This follows the
Concentration
Subject
1
2
3
4
5
6
7
S
9
10
10—'
+
+
+
+
+
+
+
+
+
+
10—6
+
+
+
+
+
+
+
+
+
+
to—'
+
+
+
0
+
+
+
+
+
+
10—8
+
0
+
0
+
+
+
+
+
+
io—'
0
0
0
0
0
0
0
0
0
0
10_b
0
0
0
0
0
0
0
0
0
0
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general observations of poor penetration of palms
and soles by any agents tested in the past (11, 12).
We have observed good inhibition of sweating
on forearms, chest, back, forehead, and axillae.
These have been the only areas tested in addi-
tion to the palms and soles. As there is definite
need for an effective agent for the control of
eccrine sweating in man, AHR-4S3 seems worthy
of further study.
SUMMAHY
1. A new anticholinergie has been found to be
very effective in suppressing eeerine sweat de-
livery by topical application.
2. This agent is capable of suppressing sweat-
ing over large areas without inducing signs of
toxicity.
3. Exaggerated exposure to this agent, including
occlusive dressings, reveals that systemic signs of
toxicity are highly unlikely from topical applica-
tion of this agent.
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